Larson Financial Group
TVTX icon

Larson Financial Group’s Travere Therapeutics TVTX Stock Holding History

Larson Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.1K Buy
189
+10
+6% +$611 ﹤0.01% 2454
2026
Q2 		$10.2K Buy
179
+12
+7% +$532 ﹤0.01% 2396
2026
Q1 		$4.96K Buy
167
+2
+1% +$60 ﹤0.01% 2616
2025
Q4 		$6.3K Buy
165
+26
+19% +$845 ﹤0.01% 2365
2025
Q3 		$3.32K Buy
+139
New +$2.61K ﹤0.01% 2510

Other funds holding TVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Larson Financial Group's TVTX Position: Q3 2026 in Review

Larson Financial Group increased its Travere Therapeutics (TVTX) stake by 5.6% in Q3 2026, buying an estimated $611 and bringing the position to 189 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Larson Financial Group first reported a position in TVTX in Q3 2025 and has held it in 5 quarters since. 158 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Larson Financial Group held 189 shares of Travere Therapeutics worth $11.1K as of Q3 2026.
  • Larson Financial Group bought 10 Travere Therapeutics shares in Q3 2026, an estimated $611.
  • Travere Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2454 holding.
  • Larson Financial Group first reported a position in Travere Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 158 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.